Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/12/2022 | $5.00 | Buy → Neutral | Sidoti |
| 12/29/2021 | $14.00 | Buy | Sidoti |
| 11/12/2021 | $16.00 → $15.00 | Buy | HC Wainwright & Co. |
Sidoti downgraded Co-Diagnostics from Buy to Neutral and set a new price target of $5.00
Sidoti initiated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $14.00
HC Wainwright & Co. reiterated coverage of Co-Diagnostics with a rating of Buy and set a new price target of $15.00 from $16.00 previously
SALT LAKE CITY, Aug. 18, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it will be hosting a booth at the 17th Annual Next Generation Dx Summit, held virtually and in-person at the Capital Hilton in Washington, D.C. on August 18-20, 2025. Cambridge Healthtech Institute's Next Generation Dx Summit is described as the nexus for international thought leaders to network and discuss diagnostic advancement and t
SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the second quarter of 2025Operating expenses of approximately $8.2 million decreased by 19.1%
SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
10-Q - Co-Diagnostics, Inc. (0001692415) (Filer)
8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
8-K - Co-Diagnostics, Inc. (0001692415) (Filer)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
4 - Co-Diagnostics, Inc. (0001692415) (Issuer)
SALT LAKE CITY, Aug. 14, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended June 30, 2025. Second Quarter 2025 Financial Results: Revenue of $0.2 million, which declined from $2.7 million during Q2 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the second quarter of 2025Operating expenses of approximately $8.2 million decreased by 19.1%
SALT LAKE CITY, July 31, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its second quarter 2025 financial results on Thursday, August 14, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results with analysts. Management on the call will include Dwight Egan, Chief Executive Officer, Brian Brown, Chief Financial Officer, and Andrew Benson, Head of Investor Relations.
SALT LAKE CITY, May 08, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (NASDAQ:CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended March 31, 2025. First Quarter 2025 Financial Results: ●Revenue of $0.1 million, which declined from $0.5 million during the Q1 2024 primarily due to timing of grant revenue recognition. The Company did not recognize any grant revenue during the first quarter 2025 ●Operating expenses of $8.6 million decreased by 18.2% from the prior year first quarter ●Operating loss of $8.6 million compared to operating loss of $10.3 million in Q
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
SC 13G/A - Co-Diagnostics, Inc. (0001692415) (Subject)
SALT LAKE CITY, April 4, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO). Prior to his new role at the Com
SALT LAKE CITY, Aug. 29, 2023 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Ivory Chang as the Company's Chief Regulatory Affairs Officer. Ms. Chang's in-depth regulatory affairs experience has included time spent with several notable names in the diagnostics industry, including Roche, Boston Scientific, BD Biosciences, Cepheid, Thermo Fisher Scientific, and more. Her background has i
SALT LAKE CITY, Nov. 1, 2022 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ:CODX) ("Co-Dx™" or the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it is pleased to welcome Mark Poritz, PhD as the Company's new Chief Scientific Officer ("CSO"). Dr. Poritz is a Harvard University and UC San Francisco educated molecular biologist with more than 30 years of experience in the application of PCR and related methods to gene cloning, drug discovery, infectious disease diagnostics and aptamer selection, who has also served as a reviewer for more than 30 different NIH/NIAID study sections focusing on inf